# A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

> **NCT05579860** · PHASE1 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 104 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Olezarsen

## Key facts

- **NCT ID:** NCT05579860
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-05
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579860, "A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05579860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*